Sign in
WithdrawnPhase 1/2

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

Key facts

Who runs it
University of Iowa
Where
Iowa City, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Mar 2023
Ended
1 Sept 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tirofiban Hydrochloride
  • Placebo
Record updated
21 September 2022
Why it stopped
PI has left the Institution

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 51 criteriaShow less

Who can take part

  • Age ≥ 18 and ≤ 90 years
  • Acute ischemic stroke (AIS)
  • Onset of AIS 6-24 hrs
  • NIHSS score ≥ 6
  • AIS due to LVO
  • core infarct <30cc or ASPECT score > 6
  • Received MT per SOC
  • TICI score of 2B, or TC post MT
  • Able to be imaged by MRI
  • Patient or their Legally Authorized Representative (LAR) has provided written informed consent

Who cannot take part

  • Previous stroke in the past 90 days
  • Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation
  • Surgery or biopsy of parenchymal organ in the past 30 days
  • Received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) in full dose within the previous 24 hours
  • Received Factor Xa inhibitors (such as Fondaparinux, apixaban or rivaroxaban) within the past 48 hours
  • Received iv tPA
  • Current participation in another research drug treatment or interventional device trial
  • Major surgery within 30 days with contra-indication to antiplatelet therapy
  • Contra-indication to antiplatelet tirofiban:; Active internal bleeding or a history of bleeding diathesis within the previous 30 days; History of thrombocytopenia following prior exposure to AGGRASTAT; History, symptoms, or findings suggestive of aortic dissection; Acute pericarditis
  • Known allergy or hypersensitivity to tirofiban
  • Clinical presentation suggested a subarachnoid hemorrhage, even if initial CT scan was normal
  • Serious systemic hemorrhage in the past 30 days
  • Pre-existing neurological or psychiatric disease which confounded the neurological or functional evaluations e.g., baseline modified Rankin score >3
  • Other serious, advanced, or terminal illness or any other condition that the investigator felt would pose a significant hazard to the patient if tirofiban therapy was initiated a. Example: known cirrhosis or clinically significant hepatic disease
  • High density lesion consistent with hemorrhage of any degree
  • Perforation of any vessel during procedure
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR >1.5
  • Glucose <50 or >400 mg/dl
  • Platelets <100,000/mm3
  • Elevated PTT above laboratory upper limit of normal
  • Creatinine > 4 mg/dl
  • Ongoing renal dialysis, regardless of creatinine
  • Abnormal PTT within 48 hours prior to randomization after receiving heparin or a direct thrombin inhibitor (such as bivalirudin, argatroban, dabigatran or lepirudin)
  • History of gastrointestinal hemorrhage or major systemic hemorrhage within 30 days, hemoglobin less than 8 g/dL on admission, INR ≥1.5, severe liver impairment as defined as AST, ALT, AP, GGT > 2 x normal
  • Creatinine clearance <30 mL/min
  • Trauma with internal injuries or ulcerative wounds in the past 30 days
  • Severe head trauma in the past 90 days
  • Systolic blood pressure persistently >180mmHg post-MT despite antihypertensive intervention
  • Diastolic blood pressure persistently >105mmHg post-MT despite antihypertensive intervention
  • Positive urine pregnancy test for women of childbearing potential
  • Hematocrit <25 %
  • Informed consent from the patient or the legally authorized representative was not or could not be obtained
  • ASPECT score < 6
  • Deployment of a stent INTRA and/or EXTRA-cranial
  • Did not receive MT
  • TICI score of 3 post MT
  • Extravasation of contrast during procedure
  • Renal dysfunction
  • Currently pregnant
  • Contraindication for MRI
  • Actual Body Weight >150kg (due to the lack of safety data)

Where in United States

  • University of Iowa Hospitals and ClinicsIowa City, United States

About the trial

What the trial wants to find out

We will recruit men and non-pregnant women of any ethnic background between the age ≥ 18 and ≤ 90 years that have acute ischemic stroke and underwent Mechanical Thrombectomy (MT) with TICI 2b or 2b following MT. These subject's will be will be randomized to placebo vs. Tirofiban after consent is obtained. This will be administered via continuous IV starting within 60 minutes of MT procedure completion. At the end of the 24 hour continuous IV dosing period a CT angiography and CT perfusion (CTA/CTP) will be obtained. The rest of the subjects inpatient hospital stay will be done per standard of care. The subject's NIHSS and modified Rankin Score (mRS) will be assessed at 90 days.

The 2 groups in the trial

  • Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))Treatment being tested

    Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.

    Treatment: Tirofiban Hydrochloride

  • Placebo ArmPlacebo, for comparison

    Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot, Exploratory Clinical Trial to Evaluate the Safety of Using Continuous IV Infusion of Tirofiban (24 Hours) Including Its Efficacy in Improving Perfusion Post Mechanical Thrombectomy in Acute Ischemic Stroke
Record updated
21 September 2022